Phenotyping of Postural Orthostatic Tachycardia Syndrome (POTS)

Last updated: June 19, 2024
Sponsor: University of Texas Southwestern Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Disease

Dysrhythmia

Fast Heart Rate (Tachycardia)

Treatment

multimodal diagnostic testing

Clinical Study ID

NCT06292104
STU-2023-0589
1R01HL166272-01A1
  • Ages > 14
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is an observational study to deeply phenotype the disorder of POTS using multiple testing modalities.

Eligibility Criteria

Inclusion

Inclusion Criteria:

POTS Patients

  • Age ≥ 14 years, able to provide informed consent (assent with parental consent forage < 18) and comply with procedures

  • Meets consensus criteria for POTS: (1) sustained increase in heart rate ≥ 30 bpmabove supine baseline within 10 min of quiet standing or upright tilt (≥ 40 bpm inindividuals 12 to 19 years of age) OR sustained upright HR (heart rate) >120 bpm, (2) absence of orthostatic hypotension, (3) symptoms with standing that improve withsitting or lying down, (4) resting supine heart rate < 100 bpm, (5) orthostaticsymptoms present for at least 6 months

  • Stable oral medication regimen for at least 14 days

Non-POTS Control Patients

  • Healthy women, age 18 - 30 years, able to provide informed consent and comply withstudy procedures

  • Does NOT meet consensus criteria for postural tachycardia syndrome

  • No symptoms of orthostatic intolerance or dysautonomia. No history of other majormedical disorder

  • Resting supine heart rate < 100 bpm

Exclusion

Exclusion Criteria:

None of the following exclusion criteria:

  • Use of amphetamine-type stimulants, diuretics, selective norepinephrine reuptakeinhibitor, anticholinergic medications (including tricyclic antidepressantmedications), fludrocortisone, desmopressin in past 14 days

  • Use of other autonomic drugs (adrenergic agents, pyridostigmine, droxidopa,triptans, ivabradine) in past 48 hours

  • Currently receiving IVIG (Intravenous immunoglobulin), subcutaneous IgG (Immunoglobulin G), or any investigational medication (in past year)

  • Infusion of iv fluids in past 7 days

  • History or evidence of another condition explaining symptoms or orthostatictachycardia (e.g. structural heart disease, CSF (Cerebrospinal fluid) hypovolemia,or severe traumatic brain injury)

Study Design

Total Participants: 350
Treatment Group(s): 1
Primary Treatment: multimodal diagnostic testing
Phase:
Study Start date:
March 05, 2024
Estimated Completion Date:
January 31, 2029

Study Description

This comprehensive multimodality deep phenotyping will improve the diagnostic approach, inform the development of new treatments, and allow the targeting of therapies to specific POTS patients. The investigators will further identify the diagnostic tools, biomarkers, and clinical outcome measures most relevant to defining the disorder in clinical practice.

The specific aim is to (1) Define clinical POTS classifications from multimodal clinical and laboratory data, (2) address exercise tolerance in POTS using metabolomic assessments, (3) evaluate novel POTS-specific patient outcome measures and (4) evaluate one year outcome data for POTS

Specific research tests will include blood work (for immunophenotyping and neurohormonal assessments), autonomic function testing, skin biopsy (to evaluate intraepidermal nerve fiber density), CO (Carbon Monoxide) rebreathing (for quantitative measurement of plasma volume and red blood cell mass), patient surveys (to characterize symptom profile and disease impact). Blood biosamples will be stored as a repository for future research questions.

Connect with a study center

  • UT Southwestern Medical Center

    Dallas, Texas 75208
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.